Reply to Letter to the Editor: ‘ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)’ by R. Contieri et al.

Annals of Oncology 2026

View at publisher

Authors: Morgan Rouprêt A

DOI: 10.1016/j.annonc.2026.01.017

Cited by: 0

References: 3

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Urinary Bladder and Prostate Research

References 3